



## Insights Into Advanced/Metastatic Cervical Cancer Wednesday, April 20, 2024

Speaker: Kathleen N. Moore, MD, MS Moderator: Sushil Bhardwaj, MD, FACP

## **AGENDA**

AGENDA	
Time (CT)	Topic
9.00 AM — 9.15 AM (15 min)	Introduction  • Program overview  • ARS questions
9.15 AM – 10.35 AM (40-min presentation; 40-min discussion)	Role of Biomarker Testing in Cervical Cancer  Overview of current data — DESTINY-PanTumor02 results  Systemic Therapy for Locally Advanced Cervical Cancer  Chemoradiation  KEYNOTE-A18 trial  INTERLACE trial  Recurrent/Metastatic Cervical Cancer  First-line therapy — IO + chemotherapy combination vs chemotherapy  Updates on KEYNOTE-826 from ASCO 2023  Ongoing trials of tisotumab vedotin combination therapy  Reaction and discussion
10.35 AM — 10.45 AM (10 min)	Break
10.45 AM — 11.45 AM (20-min presentation; 40-min discussion)	Recurrent/Metastatic Cervical Cancer  Second-line or subsequent therapy  Overview of current data and NCCN guideline updates  IO therapy  Tisotumab vedotin (innovaTV 301 trial)  AE management in patients with metastatic disease  Cemiplimab (EMPOWER trial)  T-DXd in HER2-positive tumors (IHC 3+ or 2+)  Clinical trials and future perspectives  Reaction and discussion
11.45 AM — 12.00 PM (15 min)	Key Takeaways and Meeting Evaluation